Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-2: canakinumab + docetaxel versus placebo + docetaxel in previously treated advanced NSCLC
MOH_2019-04-03_006064Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Started Jan 2019; status: completed.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-04-03_006064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-03_006064.